UK Markets closed

Genfit SA (GNFTF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
4.12000.0000 (0.00%)
At close: 09:30AM EDT
Full screen
Loading interactive chart…
  • Globe Newswire

    GENFIT Announces Signature of the Share Purchase Agreement and the Completion of its Acquisition of Versantis

    Lille (France), Cambridge (Massachusetts, United States), September 29, 2022 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases, today announced the signing of the Share Purchase Agreement and the completion of its acquisition of Versantis AG (“Versantis”) under the terms announced in its press release on September 19, 2022. As a result of this acquisition, GENFIT consolidates its position i

  • Globe Newswire

    GENFIT Reports First Half-Year 2022 Financial Results and Provides Corporate Update

    Financial highlights Cash and cash equivalents totaled €209 million as of June 30, 2022Net loss totaled €10 million for the first half 2022 Developments in our programs Patient enrollment for the double-blind part of the Phase 3 study in Primary Biliary Cholangitis (PBC) ELATIVETM completed at the end of the first semester 2022Orphan Drug Designation granted to GNS561 for the treatment of cholangiocarcinoma Agreement signed to acquire clinical-stage biotechnology company Versantis, further conso

  • Globe Newswire

    GENFIT to Acquire Clinical-stage Biopharmaceutical Company Versantis, expanding its Portfolio in Liver Diseases

    Further consolidates GENFIT’s position as a leader in acute-on-chronic liver failure (ACLF)Significantly expands GENFIT’s pipeline with VS-01-ACLF, a Phase 2 ready program based on first-in-class scavenging liposomes technology, VS-01-UCD, a pediatric program focused on urea cycle disorder (UCD), and VS-02-HE, an early-stage program focused on hepatic encephalopathy (HE)Combines Versantis’ expertise with GENFIT’s know-how in conducting complex development programs in liver diseases, to strengthe